ROBERTS BRIAN KENNETH

Average Profitability
<0.0001%
Insider Buys Quantity
11
Insider Buys Sum
$183,943.84
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of ROBERTS BRIAN KENNETH

According to the SEC Form 4 filings, ROBERTS BRIAN KENNETH, being in a position of

  1. Chief Medical Officer at Rezolute, Inc.,
    оver the last 12 months, has bought 41100 shares for $93,563, and sold 0 shares,
    over all time since 2022-05-04, has bought 67452 shares for $183,944, and sold 0 shares.

The largest purchase of all time was on 2022-05-04 and amounted to 21052 shares of Rezolute, Inc. for $79,998.

Biography of ROBERTS BRIAN KENNETH

No biography is available at this moment.

2024-06-14PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
7,600
0.0139%
$3.91$29,743+18.99%
2024-05-23PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
7,500
0.0164%
$2.69$20,138+54.1%
2024-03-28PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
500
0.0013%
$2.55$1,275+70.2%
2024-03-14PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
10,000
0.024%
$1.88$18,800+134.62%
2024-03-07PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
500
0.0013%
$1.85$925+135.08%
2024-02-26PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
2,000
0.0052%
$1.70$3,400+151.22%
2024-02-23PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
6,000
0.015%
$1.69$10,140+138.95%
2024-02-16PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
7,000
0.0171%
$1.31$9,142+196.3%
2023-07-03PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
5,000
0.0091%
$1.90$9,500-27.9%
2022-05-17PurchaseRezolute, Inc.
RZLT
Sr VP, Clinic Development
300
0.0014%
$2.95$884-31.34%
2022-05-04PurchaseRezolute, Inc.
RZLT
Sr VP, Clinic Development
21,052
0.1166%
$3.80$79,998-36.6%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.